KAZIA THERAPEUTICS LIMITED (KZIA) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTD

Explicit Guidance:

• Enrollment Timelines: Anticipates enrollment of all 36 patients in the Stage 4 Triple Negative Breast Cancer (TNBC) trial by summer 2027.
• Enrollment Timelines: Expects enrollment of ~78 patients in the HR+ extension trial (Fulvestrant + CDK4-6) to be completed by end of 2027.
• Enrollment Timelines: Projects enrollment of ~90 patients in the Phase 2 Colorectal Cancer (CRC) trial (monotherapy and combo with Pembrolizumab) by end of 2027.
• Clinical Readouts: Anticipates "meaningful" clinical updates (targeting 10–12 patient data points) throughout 2027 for TNBC, HR+, and CRC programs, rather than incremental single-patient updates.
• R&D Milestones: Expects updates on the DB1 protein degrader in early 2027.
• R&D Milestones: Expects the NDL2 (PDO1 protein degrader) asset to enter clinical trials before the end of 2027.
• Cash Position: Current cash runway extends well into 2031 (>$80M in bank).
• Strategic Timeline: Designates 2027 as a primary "year of execution" for clinical development and data generation.

Business-Segment Outlook:

• TNBC (Stage 4): Phase 1b trial expanding rapidly; anticipates radiographic assessment results as early as 3 months post-initiation. Enrolling patients regardless of PD-L1 status (amended protocol to include CPS 1–10) to test reprogramming efficacy in Pembrolizumab-ineligible cohorts.
• TNBC (Early Stage): Plans to initiate trials for Stage 2b/3 adjuvant setting (high-risk residual disease) in second half of 2027 to address unmet need in preventing recurrence.
• HR+ Breast Cancer: Launching an extension trial in second-line setting (Combination with Fulvestrant + CDK4-6) in 2027; differentiating via epigenetic reprogramming of cancer stem cells and CD8+ T cells to prevent recurrence, avoiding "fast follower" positioning.
• Colorectal Cancer (CRC): Launching Phase 2 in Q1 2027 targeting PMMR (microsatellite stable) CRC, a space where checkpoint inhibitors historically fail. Will test Paxalisib as monotherapy and in combination with Pembrolizumab.
• Pipeline (Protein Degraders): Two distinct platforms (DB1 chromatin-focused and NDL2/PDO1 nuclear-based PD-L1 degrader) are in preclinical development; NDL2 aims to cross nuclear membrane to impact post-transcriptional PD-L1.

Market and Competitive Outlook:

• Differentiation: Positions Paxalisib as distinct from other dual PI3K/mTOR inhibitors via nuclear membrane penetration enabling "non-canonical" epigenetic pathway reprogramming (targeting cancer stem cells and terminally exhausted CD8 T cells), a mechanism not observed with standard cytoplasmic-targeting inhibitors.
• Pembrolizumab Synergy: Hypothesizes Paxalisib enables checkpoint inhibitors to work in "non-responders" (low/negative PD-L1) by reprogramming the tumor microenvironment, potentially expanding the addressable market beyond CPS ≥10.
• Competitive Landscape: Explicitly avoids being a "me-too" in the crowded dual PI3K/mTOR space; focuses on safety profile (lower doses minimizing hyperglycemia/mucositis) and downstream epigenetic effects in adjuvant/recurrence settings.

Macro / Industry Outlook:

• Immune Oncology: Anticipates that targeting "slow or non-proliferating cancer stem cells" and "terminally exhausted CD8 T cells" addresses a critical gap where current immunotherapies fail to achieve deep, durable responses or prevent recurrence.
• Clinical Development Strategy: Shifts focus toward longitudinal biomarker assays (circulating tumor cells, CD8+ T cell reprogramming) as early readouts for clinical efficacy, anticipating earlier conviction before traditional PFS/OS endpoints mature.

Strategic Initiatives:

• Protocol Amendments: Amended Phase 1b TNBC protocol to include patients previously ineligible for checkpoint inhibitors (CPS 1–10).
• R&D Day: Scheduled R&D Day for December 2nd (2024) to present benchmarking data and protein degrader pipeline progress.
• Clinical Launches: Initiating HR+ and CRC trials in 2027; initiating IND-enabling studies for DB1 and NDL2 in 2027.
• Capital Efficiency: Maintaining significant cash runway (into 2031) to fund execution of multiple concurrent clinical programs without immediate dilution pressure.

Risks and Headwinds to Outlook:

• Clinical Uncertainty: Future data (2027) hinges on the successful translation of preclinical epigenetic reprogramming hypotheses into clinical benefit (PFS/OS improvements).
• Trial Complexity: Multiple simultaneous trials (TNBC, HR+, CRC, early-stage TNBC) require precise execution; delays in enrollment or data maturity in 2027 could impact valuation.
• Safety/Toxicity: While lower doses aim to reduce class-effect toxicities (hyperglycemia, mucositis), ongoing monitoring is required to confirm tolerability in combination regimens (e.g., with chemo or Pembrolizumab).
• Regulatory/Competitive: Need to prove superiority or unique value add over existing approved therapies and new ADCs in the crowded CRC and breast cancer landscapes.

Management Tone on the Future:

• Confidence: Highly confident in the "downstream epigenetic effect" and the unique ability of the molecule to cross the nuclear membrane, describing preclinical and early clinical data as "working beautifully" and "very consistently."
• Strategic Clarity: Emphasizes a shift from capital markets focus to clinical execution; explicitly states 2027 is "a year of execution" with a clear roadmap for data readouts.
• Differentiation Focus: Strong tone on avoiding "fast follower" status; aims to own the niche of epigenetic reprogramming in the PI3K/mTOR class.
• Forward-Looking Language: Frequent use of forward-looking phrases ("anticipate," "expect," "super exciting," "full line of sight") regarding 2027 milestones.

Miscellaneous:

• Investor Relations: Plans to provide "meaningful" updates (10–12 patient data points) rather than incremental "one and two" updates to satisfy investor perspectives.
• Geographic/Cohort: Trials include global preclinical work (e.g., Brisbane, Australia) and target specific high-risk cohorts (residual disease TNBC, PMMR CRC).